Search

Your search keyword '"B cells -- Forecasts and trends"' showing total 185 results

Search Constraints

Start Over You searched for: Descriptor "B cells -- Forecasts and trends" Remove constraint Descriptor: "B cells -- Forecasts and trends"
185 results on '"B cells -- Forecasts and trends"'

Search Results

1. Dimension Market Research: Antibiotics Market Expected to Reach a Revenue of USD 89.2 Billion By 2033

2. Dimension Market Research: Antibiotics Market Expected to Reach a Revenue of USD 89.2 Billion By 2033

3. BLINCYTO (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

4. AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

5. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics

6. Q1 2024 Innate Pharma SA Corporate Sales Call - Final

7. LATEST COMPANY NEWS

8. AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

9. U.S. Cell Therapy Market Size Expected to Reach USD 38.08 Bn by 2033

10. Citronella Oil Market Size Expected to Reach USD 222.69 Million by 2033

11. Immune Checkpoint Inhibitors Market to Grow at a decent CAGR during the Study Period by DelveInsight | Fianlimab (REGN-3767), Cobolimab (GSK-4069889), Tiragolumab (RG-6058), Ezabenlimab, etc

12. FDA APPROVES BLINCYTO (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

13. AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

15. BCC Research Maps the 9.2% CAGR Surge in Global Research Antibodies - A Beacon for Innovators

16. Sjogren's Syndrome Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - DelveInsight | Gilead, Daiichi Sankyo, Bayer, Vielabio, Remegen, Pfizer, Novartis, Genentech

17. Immune profiling of pediatric solid tumors

18. Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

19. Anticancer Drugs Market Size & Share to Surpass USD 303.1 billion by 2031

20. Anticancer Drugs Market Size & Share to Surpass USD 303.1 billion by 2031 | Analysis by Transparency Market Research, Inc

21. Anticancer Drugs Market Size & Share to Surpass USD 303.1 billion by 2031 | Analysis by Transparency Market Research, Inc

22. AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023

23. Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

24. The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight

25. The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight

26. Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

27. By 2032, Global Bacterial Antigens Market Size Projected to Hit USD 20.09 Million, at 6.4% CAGR: Polaris Market Research

28. PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

29. Antibody Production Market Size to Reach USD 59.1 Billion by 2032 with a CAGR of 13.2% as Per Acumen Research and Consulting

30. Antibody Production Market Size to Reach USD 59.1 Billion by 2032 with a CAGR of 13.2% as Per Acumen Research and Consulting

31. Diffuse Large B-Cell Lymphoma Market expected to rise | Companies - AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics

32. Global Cell Surface Markers Analysis Report 2023: High Uptake in Drug Discovery Applications Widens Market Prospects - Forecasts to 2030

33. Global Cell Surface Markers Analysis Report 2023: High Uptake in Drug Discovery Applications Widens Market Prospects - Forecasts to 2030

34. Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in the Market - Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, AstraZeneca, Seagen, Roche

35. Global Multiple Myeloma Market Report 2023: Sector is Expected to Reach $37.5 Billion by 2029 at a CAGR of 9.8%

36. Global Bispecific Antibody Market Report 2023: Players Include Astellas Pharma, AstraZeneca, BioAtla, BJ Bioscience and EpimAb Biotherapeutics

37. Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023

38. Leukapheresis Market Report (2023 to 2031) - Kaneka Corporation, Medica SPA, Miltenyi Biotec, Macopharma, and Terumo BCT, Inc

39. Diffuse Large B-Cell Lymphoma Pipeline Report Provides the Assessment of Mono and Combination Therapies by Stage | Major Companies - Roche, Genentech, AbbVie, and Others

40. T-Cell Lymphoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products | Major Companies - Jazz Pharmaceuticals, Celgene, Pfizer, and Others

41. Next-Generation Immunotherapies Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Regeneron, Boehringer Ingelheim, Sanofi, AstraZeneca, Roche, Merck, Incyte, GSK, Novartis

42. Next-Generation Immunotherapies Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Regeneron, Boehringer Ingelheim, Sanofi, AstraZeneca, Roche, Merck, Incyte, GSK, Novartis

43. Small Lymphocytic Lymphoma Pipeline Featuring 80+ Companies Expected to Change the Pace of the Treatment | Major Companies - Pfizer, Loxo Oncology, and Others

44. A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

45. Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

46. Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

47. Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insights Report 2023-2028: One of the Most Studied Immune Checkpoint After PD-1 and CTLA-4 - ResearchAndMarkets.com

48. Diffuse Large B-cell Lymphoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

49. Global Rituximab Biosimilars Market Report 2023: Major Players Include Pfizer, Mylan, Amgen, Teva Pharmaceutical Industries and Celltrion Healthcare

50. Rich Insights into the COVID-19 Pipeline and Clinical Trial Analysis Featuring 400+ Companies and Therapies

Catalog

Books, media, physical & digital resources